Total Revenue
Royalty Pharma Total Revenue increased by 1.4% to $630.58M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 11.0%, from $568.25M to $630.58M. Over 4 years (FY 2021 to FY 2025), Total Revenue shows relatively stable performance with a 1.0% CAGR. This is a positive signal — higher values indicate stronger performance for this metric.
Analysis
How to read this metric
An increase indicates market expansion or higher demand, while a decrease may signal market saturation or competitive pressure.
Detailed definition
Total revenue represents the gross inflow of economic benefits arising from the ordinary operating activities of the com...
Peer comparison
Standard across all public companies; peers in the medical device and diagnostics sector typically show steady growth correlated with product adoption.
total_revenueHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $554.96M | $585.77M | $575.70M | $562.05M | $535.96M | $573.46M | $565.75M | $683.97M | $538.20M | $536.31M | $596.07M | $567.98M | $537.27M | $564.69M | $593.64M | $568.25M | $578.67M | $609.29M | $621.99M | $630.58M |
| QoQ Change | — | +5.6% | -1.7% | -2.4% | -4.6% | +7.0% | -1.3% | +20.9% | -21.3% | -0.4% | +11.1% | -4.7% | -5.4% | +5.1% | +5.1% | -4.3% | +1.8% | +5.3% | +2.1% | +1.4% |
| YoY Change | — | — | — | — | -3.4% | -2.1% | -1.7% | +21.7% | +0.4% | -6.5% | +5.4% | -17.0% | -0.2% | +5.3% | -0.4% | +0.0% | +7.7% | +7.9% | +4.8% | +11.0% |
Product Breakdown
| Segment | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '23 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 |
|---|---|---|---|---|---|---|---|---|
| Income from financial royalty assets | $511.52M | $515.35M | $551.68M | — | $512.87M | $533.17M | $561.85M | $539.49M |
| Other royalty income and revenues | $16.94M | $18.07M | $20.71M | — | $24.40M | $31.52M | $31.80M | $28.76M |
| Revenue from intangible royalty assets | $33.59M | $2.54M | $1.07M | $238.00K | — | — | — | — |
| Total | $562.05M | $535.96M | $573.46M | $596.07M | $537.27M | $564.69M | $593.64M | $568.25M |
Revenue from intangible royalty assets was previously reported and has since been discontinued or reclassified. Only currently active segments are shown in the chart.
Total Revenue at Other Companies
Frequently Asked Questions
- What is Royalty Pharma's total revenue?
- Royalty Pharma (RPRX) reported total revenue of $630.58M in Q1 2026.
- How has Royalty Pharma's total revenue changed year-over-year?
- Royalty Pharma's total revenue increased by 11.0% year-over-year, from $568.25M to $630.58M.
- What is the long-term trend for Royalty Pharma's total revenue?
- Over 4 years (2021 to 2025), Royalty Pharma's total revenue has grown at a 1.0% compound annual growth rate (CAGR), from $2.29B to $2.38B.
- What does total revenue mean?
- The total amount of money a company brings in from its primary business activities before any expenses.